Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Bcr-Abl
    (3)
  • DNA/RNA Synthesis
    (1)
  • Others
    (4)
TargetMol | Tags By ResearchField
  • Cancer
    (3)
  • Immune System
    (1)
  • Inflammation
    (1)
Filter
Search Result
Results for "

breakpoint

" in TargetMol Product Catalog.
  • Inhibitors & Agonists
    4
    TargetMol | All_Pathways
  • Recombinant Protein
    4
    TargetMol | Recombinant_Protein
  • Antibody Products
    1
    TargetMol | Antibody_Products
  • Olverembatinib dimesylate
    HQP1351, GZD824 Dimesylate
    T24291421783-64-3
    Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
    • $33
    In Stock
    Size
    QTY
  • Olverembatinib
    GZD 824
    T30711257628-77-5
    Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • BCR-ABL-IN-5
    T633321795736-60-5
    BCR-ABL-IN-5 is a Bcr-Abl (Breakpoint cluster region-Abelson) kinase inhibitor that acts on Bcr-AblWT (IC50: 0.014 μM) and Bcr-AblT3151 (IC50: 0.45 μM) and exhibits some anti-proliferative effects on leukemic cells. effect.
    • $1,520
    6-8 weeks
    Size
    QTY
  • Anti-hepatic fibrosis agent 2
    T830642380421-60-1
    Compound 6k, also known as Anti-hepatic fibrosis agent 2, is an orally active inhibitor of the COL1A1 enzyme and exerts anti-fibrogenic effects by targeting the Ewing sarcoma breakpoint region 1 (EWSR1)[1].
    • Inquiry Price
    8-10 weeks
    Size
    QTY